Diprovocim-1 is a potent agonist of toll-like receptors TLR2 and TLR1 with an EC50 value of 100 pM. Diprovocim-1 was shown to synergize with anti-PD-L1 treatment, inhibiting tumor growth, generating long-term antitumor memory, and curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA.